Quanterix Corporation

NasdaqGM QTRX

Quanterix Corporation Total Assets for the quarter ending September 30, 2024: USD 411.03 M

Quanterix Corporation Total Assets is USD 411.03 M for the quarter ending September 30, 2024, a -4.20% change year over year. Total assets are the total value of all assets owned by a company, representing its resources.
  • Quanterix Corporation Total Assets for the quarter ending September 30, 2023 was USD 429.04 M, a -3.95% change year over year.
  • Quanterix Corporation Total Assets for the quarter ending September 30, 2022 was USD 446.70 M, a -12.56% change year over year.
  • Quanterix Corporation Total Assets for the quarter ending September 30, 2021 was USD 510.84 M, a 93.42% change year over year.
  • Quanterix Corporation Total Assets for the quarter ending September 30, 2020 was USD 264.11 M, a 50.45% change year over year.
Key data
Date Total Assets Current Liabilities Total Non-Current Liabilities Shareholders' Equity
Market news
Loading...
SV Wall Street
NasdaqGM: QTRX

Quanterix Corporation

CEO Dr. Masoud Toloue Ph.D.
IPO Date Dec. 7, 2017
Location United States
Headquarters Building 1
Employees 441
Sector Healthcare
Industries
Description

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Similar companies

CTKB

Cytek Biosciences, Inc.

USD 5.39

4.66%

OFIX

Orthofix Medical Inc.

USD 18.20

-0.71%

NPCE

NeuroPace, Inc.

USD 13.61

-1.09%

SGHT

Sight Sciences, Inc.

USD 2.73

-2.50%

MXCT

MaxCyte, Inc.

USD 4.35

-3.55%

RPID

Rapid Micro Biosystems, Inc.

USD 2.19

22.35%

VVOS

Vivos Therapeutics, Inc.

USD 3.90

-1.76%

CVRX

CVRx, Inc.

USD 15.46

-3.25%

SIBN

SI-BONE, Inc.

USD 17.02

1.55%

TCMD

Tactile Systems Technology, Inc.

USD 17.34

-0.97%

PRCT

PROCEPT BioRobotics Corporation

USD 71.25

-1.72%

ELMD

Electromed, Inc.

USD 33.88

-1.51%

KIDS

OrthoPediatrics Corp.

USD 24.05

0.21%

HSCS

Heart Test Laboratories, Inc.

USD 3.20

-0.93%

LUNG

Pulmonx Corporation

USD 5.84

2.82%

BBLG

Bone Biologics Corporation

USD 1.27

14.41%

StockViz Staff

February 4, 2025

Any question? Send us an email